Variant Summary
- Also known as
- EML4-ALK E6-E20
- HGVS
- —
- Variant Type(s)
- transcript_fusion
- Evidence Items
- 8
Evidence Level Distribution
Level C: 2Level D: 6
Evidence Items
Showing CIViC evidence rows where gene = EML4::ALK and variant = e6::e20.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | 2,4-pyrimidinediamine | 4 |
| C | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Crizotinib | 4 |
| C | Predictive | Supports | Sensitivity/Response | Cancer | Crizotinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Ceritinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | ALK Inhibitor TAE684 | 2 |
| D | Predictive | Does Not Support | Sensitivity/Response | Lung Non-small Cell Carcinoma | ALK Inhibitor TAE684 | 2 |
| D | Predictive | Does Not Support | Sensitivity/Response | Lung Non-small Cell Carcinoma | Crizotinib | 2 |
| D | Predictive | Does Not Support | Sensitivity/Response | Lung Non-small Cell Carcinoma | Alvespimycin | 2 |